Galmed Pharmaceuticals Stock Buy Hold or Sell Recommendation
| GLMD Stock | USD 2.86 0.01 0.35% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Galmed Pharmaceuticals is 'Strong Sell'. Macroaxis provides Galmed Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding GLMD positions.
Check out Galmed Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide. Note, we conduct extensive research on individual companies such as Galmed and provide practical buy, sell, or hold advice based on investors' constraints. Galmed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Galmed |
Execute Galmed Pharmaceuticals Buy or Sell Advice
The Galmed recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Galmed Pharmaceuticals. Macroaxis does not own or have any residual interests in Galmed Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Galmed Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Galmed Pharmaceuticals Trading Alerts and Improvement Suggestions
| Galmed Pharmaceuticals is way too risky over 90 days horizon | |
| Galmed Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (6.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Galmed Pharmaceuticals currently holds about 22.4 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Galmed Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Galmed Pharmaceuticals Stock Crosses Below 200 Day Moving Average Time to Sell |
Galmed Pharmaceuticals Returns Distribution Density
The distribution of Galmed Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Galmed Pharmaceuticals' future price movements. The chart of the probability distribution of Galmed Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Galmed Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Galmed Pharmaceuticals returns is essential to provide solid investment advice for Galmed Pharmaceuticals.
| Mean Return | 2.81 | Value At Risk | -13.4 | Potential Upside | 21.71 | Standard Deviation | 37.34 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Galmed Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Galmed Stock Institutional Investors
| Shares | Susquehanna International Group, Llp | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Two Sigma Advisers, Llc | 2024-06-30 | 0.0 | Two Sigma Securities, Llc | 2024-09-30 | 0.0 | Walleye Trading Advisors, Llc | 2024-09-30 | 0.0 | Cvi Holdings Llc | 2024-06-30 | 47.2 K | Ubs Group Ag | 2024-09-30 | 5.3 K | Tower Research Capital Llc | 2024-09-30 | 173 | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 104 | Advisor Group Holdings, Inc. | 2024-06-30 | 53.0 | Wells Fargo & Co | 2024-09-30 | 18.0 |
Galmed Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 609K | (15K) | 313K | (300K) | (345K) | (327.8K) | |
| Change In Cash | (8.1M) | (9.0M) | (4.1M) | (868K) | 848K | 890.4K | |
| Free Cash Flow | (14.9M) | (26.3M) | (32.9M) | (18.5M) | (6.1M) | (6.4M) | |
| Depreciation | 387K | 35K | 39K | 42K | 31K | 29.5K | |
| Other Non Cash Items | (63K) | (285K) | 13K | 485K | (280K) | (266K) | |
| Capital Expenditures | 90K | 12K | 44K | 11K | 4K | 0.0 | |
| Net Income | (20.5M) | (28.8M) | (32.5M) | (17.9M) | (6.9M) | (7.3M) | |
| End Period Cash Flow | 16.0M | 7.1M | 3.0M | 2.1M | 3.0M | 2.8M | |
| Investments | 6.7M | 16.6M | 11.5M | 17.6M | 500K | 525K | |
| Change To Netincome | 1.7M | 2.1M | 1.3M | 1.8M | 1.6M | 2.2M |
Galmed Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Galmed Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Galmed Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Galmed stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 2.84 | |
β | Beta against Dow Jones | -0.26 | |
σ | Overall volatility | 37.90 | |
Ir | Information ratio | 0.07 |
Galmed Pharmaceuticals Volatility Alert
Galmed Pharmaceuticals is showing large volatility of returns over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Galmed Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Galmed Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Galmed Pharmaceuticals Fundamentals Vs Peers
Comparing Galmed Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Galmed Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Galmed Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Galmed Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Galmed Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Galmed Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Galmed Pharmaceuticals to competition |
| Fundamentals | Galmed Pharmaceuticals | Peer Average |
| Return On Equity | -0.53 | -0.31 |
| Return On Asset | -0.29 | -0.14 |
| Current Valuation | (7.86 M) | 16.62 B |
| Shares Outstanding | 1.66 M | 571.82 M |
| Shares Owned By Insiders | 1.28 % | 10.09 % |
| Shares Owned By Institutions | 0.48 % | 39.21 % |
| Number Of Shares Shorted | 17.42 K | 4.71 M |
| Price To Earning | (6.79) X | 28.72 X |
| Price To Book | 0.26 X | 9.51 X |
| EBITDA | (6.87 M) | 3.9 B |
| Net Income | (6.91 M) | 570.98 M |
| Cash And Equivalents | 22.4 M | 2.7 B |
| Cash Per Share | 0.89 X | 5.01 X |
| Total Debt | 41 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 8.48 X | 2.16 X |
| Book Value Per Share | 33.01 X | 1.93 K |
| Cash Flow From Operations | (6.14 M) | 971.22 M |
| Short Ratio | 0.27 X | 4.00 X |
| Earnings Per Share | 69.72 X | 3.12 X |
| Target Price | 12.0 | |
| Number Of Employees | 3 | 18.84 K |
| Beta | 0.8 | -0.15 |
| Market Capitalization | 4.74 M | 19.03 B |
| Total Asset | 16.63 M | 29.47 B |
| Retained Earnings | (192.95 M) | 9.33 B |
| Working Capital | 10.49 M | 1.48 B |
| Current Asset | 23.38 M | 9.34 B |
| Current Liabilities | 2.54 M | 7.9 B |
| Net Asset | 16.63 M |
Galmed Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Galmed . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Galmed Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Galmed Pharmaceuticals? Buying financial instruments such as Galmed Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Galmed Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sport Products Thematic Idea Now
Sport Products
Companies manufacturing sporting goods and accessories. The Sport Products theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sport Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Galmed Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.